Tommy G. Thompson - 22 Jul 2026 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Reporting relationship: Director
Issuer ticker: UTHR
Reported as of: 22 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jul 2026, 16:45:32 UTC
Prior SEC filing: 26 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ John S. Hess, Jr. under Power of Attorney

Key filing fact

Tommy G. Thompson filed Form 4 for UNITED THERAPEUTICS Corp (UTHR) on 23 Jul 2026.

Key facts

This page summarizes Tommy G. Thompson's Form 4 filing for UNITED THERAPEUTICS Corp (UTHR).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 23 Jul 2026, 16:45.

Change

Previous filing in this sequence was filed on 26 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001324863 Primary reporting owner

Thompson Tommy G

Relationship: Director
Address: C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING
Signature: /s/ John S. Hess, Jr. under Power of Attorney
Signature date: 23 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

UTHR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8,480
Date: 22 Jul 2026
Ownership: Direct
Footnotes: F1

UTHR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8,200
Date: 22 Jul 2026
Ownership: by Trust

UTHR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 5,800
Date: 22 Jul 2026
Ownership: by Family LLC

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

UTHR transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +380
Change %
Price: $0.000000^*
Shares after: 380
Date: 22 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 380
Exercise price: $0.000000
Footnotes: F2, F3, F4, F5

UTHR transaction Derivative

Stock Option

Award

Transaction value
Shares: +1,190
Change %
Price: $0.000000^*
Shares after: 1,190
Date: 22 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,190
Exercise price: $527.07
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Includes 880 shares of common stock issued on July 8, 2026, as the result of the July 7, 2023 vesting of RSUs for which the reporting person elected to defer receipt of shares.

Footnote F2

Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

Footnote F3

Annual non-employee director award.

Footnote F4

Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.

Footnote F5

Not applicable as restricted stock units do not have an expiration date.